BioPharm International Editors


FDA Approves $3.5 Million Hemophilia B Gene Therapy

CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.

Merck Announces $1.35 Billion Acquisition of Imago BioSciences

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement

The agreement aims to develop integrated technology for large-scale exosome production.

Regeneron and Cytomx Announce $2 Billion Oncology Collaboration

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

MilliporeSigma Invests $286 Million in US Drug Safety Testing Capacity

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

Bio-Rad Introduces Pioneer Antibody Discovery Platform for Therapeutic Development

The Pioneer Antibody Discovery Platform is a new antibody discovery service specifically designed to develop best-in-class biologic candidates.

Gelomics and Rousselot Biomedical Announce 3D Cell Culture Kits Based on Gelatin Methacryloyl

Rousselot Biomedical will supply Gelomics with its gelatin methacryloyl, a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.

FDA Approves Injection Designed to Delay Onset of Type 1 Diabetes

Tzield (teplizumab-mzwv) injection is the first FDA-approved therapy designed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older.

Biotech Startup Raises $5.4M to Develop AI-Designed Protein Machines and Cell Factories

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.